Fred Hutch Cancer Center | Strategic Alliance Partners

Evan T. Hall, MD, MPhil, discusses the limited potential for immunotherapy rechallenge in patients with RCC and challenges with later-line RCC management.

Petros Grivas, MD, PhD, details questions and considerations for integrating perioperative durvalumab plus neoadjuvant chemotherapy into MIBC management.

A network meta analysis compared the efficacy of BTK inhibitors in patients with high-risk R/R chronic lymphocytic leukemia.

Evan Y. Yu, MD, discusses the potential utility of AR degradation, mutation inhibition, and suppression for patients with metastatic prostate cancer.

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.

Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.

E. Gabriela Chiorean, MD, FASCO, discusses the FDA approval of encorafenib plus cetuximab and chemotherapy for patients with BRAF V600E–mutated mCRC.

Gentry King, MD, discusses positive and negative outcomes following the phase 3 CELESTIAL and COSMIC-312 trials in patients with hepatocellular carcinoma.

Gentry King, MD, highlights the evolution of treatments in the hepatocellular carcinoma landscape and the impact of the phase 3 HIMALAYA trial.

Ryan Cassaday, MD, discussed insights from trials investigating blinatumomab in patients with B-ALL that were reported at the 2024 ASH Annual Meeting.

Evorpacept plus TRP produced superior ORR, DOR, and PFS outcomes vs TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer.

E. Gabriela Chiorean, MD, FASCO, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.

Rahul Banerjee, MD, FACP, discusses treatment de-escalation strategies with the use of bispecific antibodies in patients with relapsed multiple myeloma.

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

Dr Shadman discusses key findings and implications from trials that were presented at the 2024 ASH Annual Meeting investigating zanubrutinib in CLL.

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.

Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.

Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.

Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.

Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion LUNG-2 trial.

AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding.

Rahul Banerjee, MD, FACP, discusses his hopes for the future of bispecific antibody therapy for patients with multiple myeloma.

Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.

Rahul Banerjee, MD, FACP, discusses clinical benefits derived when reducing the dosing of bispecific antibodies in the management of multiple myeloma.

Rahul Banerjee, MD, FACP, discusses the clinical impact of dose modification studies on the treatment of patients with multiple myeloma.

Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.

Rahul Banerjee, MD, FACP, discusses the ongoing investigation into different dosing schedules of bispecific antibodies in multiple myeloma.